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as entecavir and tenofovir have low risk of resistance, for
historical reasons many patients in Asia have been exposed
to drugs with low genetic barrier to resistance.
To detect drug resistance, vigilant monitoring of HBV DNA
level is essential. Virological breakthrough is deﬁned as a
rise of HBV DNA level by 10-fold during antiviral therapy
and is indicative of drug resistance. When virological
breakthrough develops, salvage antiviral therapy with a
drug without cross-resistance should be initiated as soon
as possible to ensure treatment success. Nevertheless, in
some cases the selection of salvage therapy is not always
straightforward. For example, while adefovir dipivoxil or
tenofovir is commonly used to treat lamivudine resistance,
the mutant rtA181T/V confers resistance or reduced
sensitivity to all three agents but remains sensitive to
entecavir.
Drug resistance testing is used to identify the culprit mutant
and aids clinicians in choosing the optimal antiviral agent. In
a recent survey, drug resistance testing altered management
in over half of the cases. Two types of commercial assays
are available direct sequencing (TRUGENE HBV, Siemens
Health Care Diagnostic Solutions, and Afﬁgene HBV DE/3TC
Assay, Sangtec Molecular Diagnostics AB) and reverse
hybridization (INNO-LiPA DR Version 2.0, Innogenetics).
Direct sequencing of the polymerase gene has the advantage
of identifying both known and previously unreported
mutations. However, the test may be falsely negative
if the mutants constitute less than 20% of the whole
population. Besides, the detection of new mutations is
common and may not necessarily represent drug resistance.
In vitro phenotypic analysis is required to conﬁrm decreased
susceptibility to treatment.
In contrast, hybridization assays are more sensitive and
can detect mutants that constitute only 5% of the
whole population. Nevertheless, one major limitation of
hybridization assays is that only known mutations can be
detected. When new drug-resistant mutations are reported,
the test needs regular updating.
Mass spectroscopy represents an inexpensive and sensitive
method that may detect mutant population that represents
5% of the overall population. Ultradeep pyrosequencing is
another more sensitive technique. These new technologies
may overcome the limitations of existing assays and warrant
further validation.
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Inﬂuenza continues to be a serious respiratory disease
globally and can become a major public health threat when
a novel virus with pandemic potential emerges. Classical
inﬂuenza presents with the sudden onset of fever followed
by systemic symptoms of muscle aches, malaise and a cough.
During an outbreak or epidemic, the accuracy of a clinician’s
diagnosis of inﬂuenza may have a PPV 79 87% and NPV
39 75%, while the PPV drops to 44% during periods of low
activity. Atypical presentations may also occur especially in
young children and the elderly, and the severity of symptoms
may vary from mild to severe. Further other viral infections
can present as inﬂuenza-like-illness. For these reasons, the
laboratory diagnosis of inﬂuenza may be required to assist
the antiviral treatment and management of patients in the
community and in hospital.
Many laboratories have focused on molecular diagnostics
(nucleic acid ampliﬁcation) following the avian inﬂuenza
outbreak in late 2003, then the H1N1 2009 pandemic,
because of this technologies high sensitivity, speciﬁcity,
potential for automation and staff safety considerations.
The perceived cost, minimum sample volume requirements
for batched testing using commercial platforms, and
the requirement for trained staff to ensure quality and
maintenance procedures are followed, has limited the
introduction of this technology into some laboratories.
Classical diagnostic methods involve the culture of
viable virus and the direct detection of viral antigen
by immunoﬂuoresence or immunocromatography assays.
Culture remains the gold standard, while the sensitivity
and speciﬁcity of antigen detection assays is limited by
the technology used, and their clinical usefulness (PPV and
NPV) is inﬂuenced by the level of inﬂuenza activity in the
community. An important consideration is the diagnostic
yield of inﬂuenza detection assays which can be affected
by a number of factors including the natural course of viral
shedding during an infection, the severity of disease, the
timing of a patient’s presentation for sampling and the type
and quality of respiratory sample obtained.
The role of the laboratory has changed following the recent
H1N1 pandemic. Public Health specialists now require
both positive and negative results in a timely manner to
assist the management of outbreaks. Clinicians also require
inﬂuenza A subtype and antiviral resistance information, all
of which requires the use of sensitive molecular assays.
The renewed focus on inﬂuenza surveillance has raised
the importance of other non-inﬂuenza respiratory viruses
and their detection. There are an increasing range of
commercial assays becoming available utilizing differing
molecular methods and primer designs. These automated
fully validated assays, with quality controlled reagents and
the auto-calling of results offer increased sensitivity and
rapid turnaround times for the detection of a wide range
of respiratory viruses. Few head-to-head comparisons are
available to allow assessment of their clinical usefulness.
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Inﬂuenza pandemics cause signiﬁcant human mortality. In
the 20th Century there were three recorded pandemics that
resulted in over 50 million human deaths. During March
and early April 2009, an H1N1 virus lineage previously
undetected in humans emerged in Mexico and the United
States. This novel virus was sufﬁciently antigenically
divergent from seasonal H1N1 that the human population
was immunologically naive. Subsequently this virus spread
rapidly via human-to-human transmission, developing into
the ﬁrst inﬂuenza pandemic in 40 years. Despite global
concern regarding pandemic inﬂuenza, the emergence
pathways of pandemic strains remained obscure. Here
the evolutionary history and inferred date of introduction
to humans of each of the genes for all four pandemic
inﬂuenza strains were calculated. Phylogenetic trees were
inferred using the neighbor-joining distance method, with
genetic distances calculated by maximum likelihood under
the Hasegawa Kishino Yano (HKY) model with gamma-
distributed rates among sites. Parameters of this model
were estimated using maximum likelihood on an initial
tree. Temporal phylogenies and rates of evolution were
inferred using a relaxed molecular clock model that allows
rates to vary among lineages within a Bayesian Markov
chain Monte Carlo (MCMC) framework. A model comprising
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a codon-position-speciﬁc HKY substitution model was used.
Results show that all three pandemic inﬂuenza strains
of the 20th century, plus to 2009 H1N1 pandemic virus,
were generated through a series of multiple reassortment
events and emerged over a period of years before pandemic
recognition. The results also indicated that each of the 20th-
Century pandemic strains was produced by reassortment
between the previously circulating human virus and at least
one virus of animal origin. The novel gene segments for
the H2N2/1957 and H3N2/1968 pandemics seem to have
originated from avian hosts, but the zoonotic sources
of the introduced viral gene segments for the 1918
pandemic remain ambiguous. Evidence suggests that, over
a number of years, avian gene virus segments entered
mammalian populations where the viruses may have
undergone reassortment with the prevailing human virus.
Given the frequent interspecies transmission of inﬂuenza
viruses between swine and humans, it is most likely
that such reassortment events occurred in swine before
pandemic emergence. This scenario is precisely describes
the emergence of the 2009 H1N1 virus which involved a
series of reassortment events in pigs that involved viruses
of avian, swine and human origin.
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Inﬂuenza causes annual recurrent health impact on
the society. In Hong Kong, about 130 580 per 100,000
elderly individuals are hospitalized annually for inﬂuenza-
associated complications such as pneumonia, exacerbation
of chronic obstructive pulmonary diseases or asthma,
and acute cardiovascular events. While antiviral agents
speciﬁc for inﬂuenza have been available for many years,
the practice of antiviral treatment for these hospitalized
patients still varies from centre to centre. On one extreme,
the duration of 48 hours after illness onset is still regarded
as the “cut-off” for cost-effective treatment. Whereas, in
view of the often higher viral load and prolonged shedding
of viruses seen in patients with severe disease, some
clinicians would offer treatment even beyond the golden
period of “48 hours”. We have shown that treatment with
neuraminidase inhibitor for the high-risk group hospitalized
for laboratory conﬁrmed seasonal inﬂuenza could accelerate
viral clearance, shorten viral shedding, reduce the length
of hospital stay, allow earlier discontinuation of oxygen
therapy and decrease mortality. For instance, we have
shown that initiation of oseltamivir within 96 hours after
illness onset was associated independently with a decrease
in mortality (OR: 0.26, 95%CI: 0.08 0.87).
Our experience from the 2009 pandemic suggested that
patients with severe pneumonia often had a higher viral
load at presentation (1.3 logs higher than those with
mild infection), and most of them had viral RNA detected
from extrapulmonary sites. Clinical recovery was associated
with rapid viral clearance following a standard course of
neuraminidase inhibitor treatment. However, patients with
severe pneumonia often exhibited a prolonged course of
viral shedding, especially from the lower respiratory tract,
despite the administration of neuraminidase inhibitor. This
raised the consideration of higher dose and more sustained
antiviral regime for selected high-risk patients.
The development of drug resistance for a highly mutable
virus like inﬂuenza is always a concern. The older class of
anti-inﬂuenza agent, adamantanes, is well known for such
problem. Given the known resistance of the 2009 pandemic
H1N1 virus to this class of anti-inﬂuenza compounds,
the choice of treatment and prophylaxis is limited to
neuraminidase inhibitors. While a huge number of doses
of neuraminidase inhibitors, mainly oseltamivir and to a
small extent zanamivir, have been administered during
the pandemic; resistance remains at a low level as what
one would expect from the natural mutation of this virus.
Majority of the reported cases of neuraminidase inhibitor-
resistance were from low-dose or prolong administration in
immunosuppressed patients.
The administration of effective antiviral compounds remains
an important component in the clinical management of
inﬂuenza infection, especially for those with a high risk of
developing severe complications.
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Hepatitis B Virus (HBV) has evolved a unique life cycle that
results in the production of enormous viral loads during
active replication without actually killing the infected cells
directly. Two of the key events in the viral life cycle of
HBV involve ﬁrstly the generation of a covalently closed
circular (ccc) DNA transcriptional template either from input
genomic DNA or newly replicated capsid-associated DNA and
secondly, reverse transcription of the viral pregenomic RNA
to form progeny HBV DNA genomes. New data are emerging
regarding the epigenetic control of cccDNA which may
represent another key factor involved in the pathogenesis
and natural history of the disease. A high rate of viral
turnover, combined with an error-prone polymerase, results
in a very high frequency of mutational events during
HBV replication. Not surprisingly then, particular selection
pressures, both endogenous (host immune clearance) and
exogenous (vaccines and antiviral drugs), readily select out
escape mutants.
Antiviral drug resistance is associated with point mutations
in the HBV polymerase/reverse transcriptase (rt) and ﬁve
major “pathways” of antiviral drug-resistance associated
substitutions have now been identiﬁed. The ﬁrst is
the rtM204V/I pathway which is selected out by the
L-nucleosides Lamivudine (LMV) and Telbivudine (LdT). The
second is the rtA181T/V pathway selected by both the
L-nucleosides as well as the Acyclic Phosphonates Adefovir
(ADV) and Tenofovir (TFV) and is also referred to as
the “Shared Pathway”. The third or rtN236T pathway is
associated with resistance to ADV and reduced sensitivity to
TFV whilst the double mutant, rtA181T/V+rtN236T, in the
double resistance pathway which has been recently linked
to TFV resistance as well as ADV treatment failure. The ﬁfth
or the D-Cyclopentane pathway is associated with entecavir
resistance and typically requires at least three changes:
